Open-label Study of TAK-875

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of treatment with TAK-875 in diabetic patients.

• Phase: Phase 3

Details

• Lead Sponsor: Takeda

Criteria

Inclusion Criteria:

1. The participant is an outpatient.

2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria:

1. The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.

2. The participant is considered ineligible for the study for any other reason by the investigator or sub-investigator.